The Food and Drug Administration moved quickly on Friday to grant an emergency authorization to Gilead’s remdesivir, an experimental antiviral shown this week to hasten the recovery of patients hospitalized with COVID-19. The clearance is not equivalent to a standard approval, and specifies that distribution of the drug will be controlled by the U.S. government.
For further information, see Biopharma Dive (https://www.biopharmadive.com/news/gilead-remdesivir-coronavirus-fda-emergency-authorization/577027/)
